The diagnosis and treatment of kidney cancer have evolved rapidly in recent years. Although the incidence of renal cell carcinoma (RCC) has increased, survival rates have improved substantially.
As incidental detection of small, indolent kidney tumors has become more common, active surveillance, robotic-assisted surgical techniques, and minimally invasive procedures such as thermal ablation have gained popularity.
In its early stages, kidney cancer usually does not cause symptoms. However, as the tumor grows, signs and symptoms may begin to appear, including:
If you experience any of these symptoms, it is important to consult a healthcare professional for an appropriate evaluation.
Surgical removal of the tumor (partial or radical nephrectomy) remains the gold standard for treating kidney tumors.
Tumor selection for partial nephrectomy has traditionally been determined by the tumor’s anatomical location, stage, and other characteristics that may limit the feasibility of complete tumor resection.
Randomized clinical trials have evaluated the potential of nephron-sparing approaches to preserve kidney function and reduce the long-term morbidity associated with having a solitary kidney.
Cryoablation is an increasingly used treatment option for stage I kidney cancer. In 2009, the American Urological Association included ablation in its treatment guidelines for stage I kidney cancer.
The National Comprehensive Cancer Network added ablation to its guidelines in 2018. Microwave ablation has increasingly been recognized as a valuable treatment option for kidney cancer, particularly for patients with contraindications to general anesthesia, high surgical risk, or a need to maximize preservation of kidney function particularly for patients with contraindications to general anesthesia, high surgical risk, or a need to maximize preservation of kidney function.
(Favi et al., Cardiovasc Intervent Radiol. 2019)

Cryoablation

Microwave Ablation

Irreversible Electroporation (IRE)
Thermal ablation is primarily used to treat small, unresectable tumors in selected patients who are not surgical candidates or whose tumors have not responded to chemotherapy or radiation therapy, for example: